Immunoparalysis and adverse outcomes from critical illness. - Test2 - elhamkhani - TriplyDB

Immunoparalysis and adverse outcomes from critical illness.

Immunoparalysis and adverse outcomes from critical illness.

http://www.wikidata.org/entity/Q36775843

about

Endotoxin-Induced Tryptophan Degradation along the Kynurenine Pathway: The Role of Indolamine 2,3-Dioxygenase and Aryl Hydrocarbon Receptor-Mediated Immunosuppressive Effects in Endotoxin Tolerance and Cancer and Its Implications for Immunoparalysis Is the developmentally immature immune response in paediatric sepsis a recapitulation of immune tolerance?Assessment of the internal genes of influenza A (H7N9) virus contributing to high pathogenicity in mice Efficacy of β-Lactam-plus-Macrolide Combination Therapy in a Mouse Model of Lethal Pneumococcal Pneumonia A new reassortment of influenza A (H7N9) virus causing human infection in Beijing, 2014 Identification of pediatric septic shock subclasses based on genome-wide expression profiling.Divergent adaptive and innate immunological responses are observed in humans following blunt trauma.Induced expression and functional effects of aquaporin-1 in human leukocytes in sepsis MAPK signaling drives inflammation in LPS-stimulated cardiomyocytes: the route of crosstalk to G-protein-coupled receptors.Priming of neutrophils and differentiated PLB-985 cells by pathophysiological concentrations of TNF-α is partially oxygen dependent Autophagy-related IRGM polymorphism is associated with mortality of patients with severe sepsis Immunity, inflammation and sepsis: new insights and persistent questions.Inhibition of caspase-1 activation in Gram-negative sepsis and experimental endotoxemia Multiple MoS2 Transistors for Sensing Molecule Interaction Kinetics.Changes of monocyte human leukocyte antigen-DR expression as a reliable predictor of mortality in severe sepsis.Very low birth weight neonates who survive early-onset sepsis do not have an increased risk of developing late-onset sepsis An integrated microfluidic platform for in situ cellular cytokine secretion immunophenotyping Early sepsis does not increase the risk of late sepsis in very low birth weight neonates Systemic varicella-zoster virus infection in two critically ill patients in an intensive care unit.Cyclophilin A protects mice against infection by influenza A virus.Investigating the role of Natural Killer T-cells in Gram negative infections of patients with type 2 diabetes mellitus.Prevention of nosocomial infections in critically ill patients with lactoferrin (PREVAIL study): study protocol for a randomized controlled trial Microbial profiling of dental plaque from mechanically ventilated patients The changing immune system in sepsis: is individualized immuno-modulatory therapy the answer?Immunomodulatory therapy for sepsis: an update.Lymphocyte count as a sign of immunoparalysis and its correlation with nutritional status in pediatric intensive care patients with sepsis: A pilot study.Pediatric Perioperative Stress Responses and Anesthesia.Pseudomembranous aspergillar tracheobronchitis in a non-neutropenic critically ill patient in the intensive care unit.Increased inflammatory markers with altered antioxidant status persist after clinical recovery from severe sepsis: a correlation with low HDL cholesterol and albumin.Targeted delivery of siRNA to cell death proteins in sepsis.Low monocyte HLA-DR expression as an indicator of immunodepression in very low birth weight infants.Potentiation and tolerance of toll-like receptor priming in human endothelial cells.Early immune anergy towards recall antigens and mitogens in patients at onset of septic shock.A Systemic Inflammation Mortality Risk Assessment Contingency Table for Severe Sepsis.Two circulating neutrophil populations in acute inflammation in mice.Granulocytic myeloid-derived suppressor cells inversely correlate with plasma arginine and overall survival in critically ill patients.Innate and adaptive immune dysregulation in critically ill ICU patients.Dietary Fish Oil Decreases the Proportion of Classical Monocytes in Blood in Healthy Mice but Increases Their Proportion upon Induction of Inflammation Aflatoxin B Promotes Influenza Replication and Increases Virus Related Lung Damage via Activation of TLR4 Signaling

P2860

Q26765777-DC21E178-826B-44F4-87ED-5AA13AA25CB3 Q26999060-A721C191-440A-452F-89D0-F6EA3A08B731 Q28386118-26190C5B-A04C-4F5C-95CF-0FD99555AC01 Q28390204-A93154E9-DB20-468C-8362-7EA0A6A2D783 Q28602120-F29C4B3E-D3D8-405F-852E-8A196B1FA256 Q30438982-56D4016F-3F8B-46EA-B73F-6645824A1587 Q33526479-CF0E6614-30C9-4A99-A893-5A44644257D1 Q33752063-97997B79-CEEB-418A-8C3F-77627A03EBB4 Q34505110-E2717AE5-C8DA-47CA-91EA-8F96905CCD35 Q35082272-445275FC-748A-4391-A9C2-EE7D7D1093CD Q35120236-D9A600CA-0629-4636-8247-98A41CA68107 Q35566992-1750387B-FE1F-40D2-A668-0CD3DBE417D0 Q35567246-1B269309-D248-4DAF-BE4B-E447BE6CBAB7 Q35650953-80155B27-1D5B-4A4B-950F-3808DE17EF0A Q35908140-BDFF1E4A-E2F7-44B8-91A8-24B268E3C382 Q36291304-E0B6227B-EDFE-4CD1-A1A4-8C35E4679BE3 Q36427709-2B526405-0661-4CFB-ADF7-CE0330511863 Q36756012-F5702D54-7A75-4912-83BF-A7AE8AAD5C2D Q37014361-B8E5AAB3-1B30-4A2F-991A-FBA4A31F07CA Q37049668-811C6E57-0F7B-4681-AA45-49E54DF1641F Q37079302-D815FF31-2507-4D49-899B-78291D8A28D7 Q37295042-158739D7-8E03-4CB7-A46F-6857879C86F2 Q37422718-C1B232D7-E8C1-4E77-B863-8F35F69EEDB5 Q37563023-686BD0E8-462C-404D-B475-F945E5137C28 Q37949639-E52CD434-B795-40EE-A7F6-0175754A9210 Q39095731-E2BB8178-2315-4F34-BD5D-5BDDB829D0A5 Q39143987-F7226390-80E6-4993-BA87-14ECF51D2A5F Q40164347-0C960BA7-B2A5-409E-A980-A0694BB870CF Q40976509-CE8680B1-35A1-4E97-A516-94F88462F1F3 Q41768037-472E55BE-879A-4E64-9A24-08E0E4C0727F Q45199847-BEEF157C-51B7-4DFD-AE12-B6F18D14115A Q46412054-F5C77B5E-9ACC-4803-9D8C-A5B31019C1A1 Q49259114-015ED4CC-C496-4855-BEB5-60E653A8AAE4 Q50326760-AD953151-E3BB-4E30-A551-EAEED96B5D27 Q51339772-6C11DB0C-F6C4-4B3A-B5AF-8C283B69D07F Q53160619-78FDDC42-97BB-4F3E-AAE4-D59D05075664 Q55653469-55CC32E1-4F7A-452D-AD68-F52A360C6584 Q57980492-937E0B51-9193-4BDA-AD8D-655E673C0FC1 Q58583834-8F38D6E4-4101-4D06-ABD0-BAE66F53951C

P2860

Immunoparalysis and adverse outcomes from critical illness.

http://www.wikidata.org/entity/Q36775843

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

2008年论文

@zh

2008年论文

@zh-cn

name

Immunoparalysis and adverse outcomes from critical illness.

@ast

Immunoparalysis and adverse outcomes from critical illness.

@en

type

label

Immunoparalysis and adverse outcomes from critical illness.

@ast

Immunoparalysis and adverse outcomes from critical illness.

@en

prefLabel

Immunoparalysis and adverse outcomes from critical illness.

@ast

Immunoparalysis and adverse outcomes from critical illness.

@en

P1433

Q36775843-C94178BB-FCC7-42BB-9AA9-C8CD5A4BE717

P1476

Q36775843-660CD3B5-9CF1-4DB0-B54E-BC7F3073FC6E

P2093

Q36775843-2A7B1949-3457-47F4-AFD1-83570F7B2F84

Q36775843-E17E3221-4129-472E-809F-5887055E5DA4

P2860

Q36775843-00D2DC69-F6F3-4F36-ABCB-309966540FA0

Q36775843-02B9E80C-3369-46B0-8789-C0AFB56DDF35

Q36775843-08EF9053-324C-40F9-BCC5-97E29E91A15B

Q36775843-0A154D61-A495-43E0-8156-F9ACD26546CD

Q36775843-14BF192F-E961-4C62-9711-0F7629A9D556

Q36775843-24DEB089-F20A-435C-95B5-37BC5CCF8DA3

Q36775843-36BAE7E0-6227-4B10-916F-62E34A5CE981

Q36775843-38424BC6-0D52-49E2-B6FA-95E76DAA743C

Q36775843-3F88C8F0-C612-4EB7-ADE5-D099202EEF23

Q36775843-42DD0AFC-E742-4884-BCBC-30B6CE4C70FF

P304

Q36775843-3D59A06A-8D7C-4923-8D12-7B96BB6E5359

P31

Q36775843-53DF7A8A-1D5C-4EBC-9940-02B422E28C4A

P356

Q36775843-E23F41A5-1A4C-4A36-9786-2A3A9B7FE55F

P433

Q36775843-9E7A0D25-891B-4E3C-AB4C-ECBC1C003CDC

P478

Q36775843-E50EA8AD-1573-4DAB-ABD3-A7EC86FFA037

P577

Q36775843-FE3F54E1-8F3A-43E7-87B7-DAAA4B2A2762

P5875

Q36775843-512E8C13-F09F-4BF8-B370-8023BCB77092

P698

Q36775843-3FC9074C-D60E-4D3F-A109-396D27FB2B60

P932

Q36775843-F021F188-27A1-4F06-82D0-E1BE2C83542D

P356

J.PCL.2008.02.009

P1433

Pediatric Clinics of North America

P1476

Immunoparalysis and adverse outcomes from critical illness.

@en

P2093

Mark W Hall

http://www.w3.org/2001/XMLSchema#string

W Joshua Frazier

http://www.w3.org/2001/XMLSchema#string

P2860

G-CSF and GM-CSF for treating or preventing neonatal infections

Insulin inhibits intranuclear nuclear factor kappaB and stimulates IkappaB in mononuclear cells in obese subjects: evidence for an anti-inflammatory effect?

Tumor cells deactivate human monocytes by up-regulating IL-1 receptor associated kinase-M expression via CD44 and TLR4

Rapid up-regulation of IRAK-M expression following a second endotoxin challenge in human monocytes and in monocytes isolated from septic patients

Dysregulation of LPS-induced Toll-like receptor 4-MyD88 complex formation and IL-1 receptor-associated kinase 1 activation in endotoxin-tolerant cells

A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. The XOMA Sepsis Study Group

Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab')2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels

A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: results of a prospective, multicenter, randomized, controlled trial. The E5 Sepsis Study Group

Morphine-induced macrophage apoptosis: the role of transforming growth factor-beta

Dysfunction of polymorphonuclear leukocytes in uremia: role of parathyroid hormone.

P304

647-68, xi

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.PCL.2008.02.009

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

55

http://www.w3.org/2001/XMLSchema#string

P577

2008-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5348017

http://www.w3.org/2001/XMLSchema#string

P698

18501759

http://www.w3.org/2001/XMLSchema#string

P932

2474674

http://www.w3.org/2001/XMLSchema#string